Related Experiment Video
Updated: Jul 7, 2026

Unveiling Histone Proteoforms using 2D-TAU Gel Electrophoresis
Published on: October 18, 2024
Transforming pathways unleashed by a HDAC2 mutation in human cancer
S Ropero1, E Ballestar, M Alaminos
1Cancer Epigenetics Laboratory, Spanish National Cancer Centre (CNIO), Madrid, Spain.
Abstract:
Although disruption of histone modification patterns is a common hallmark of human cancer, our knowledge of the mechanistic role of histone-modifying enzymes in its generation is very limited. We have recently identified an inactivating mutation in the histone deacetylase-2 (HDAC2) in sporadic carcinomas with microsatellite instability and in tumors arising in individuals with hereditary nonpolyposis colorectal cancer syndrome. Since HDAC2 seems to be a central player in epigenetic gene repression, we wondered whether HDAC2-truncating mutations conferred a particular expression signature on these cancer cells. Using unsupervised clustering analysis in microsatellite-unstable colorectal cancer cell lines, we have found that HDAC2 mutant cells (RKO and Co115) show a characteristically different expression microarray signature from HDAC2 wild-type cells (HCT-116, SW48, HCT-15 and LoVo). HDAC2 mutant cells exhibit upregulation of tumor-promoting genes, such as those of tyrosine kinases, mediators of cell cycle progression and angiogenic factors. The overexpression of these genes is associated with a loss of HDAC2 recruitment and a gain of histone H4 hyperacetylation in their particular 5'-end promoters, as observed by chromatin immunoprecipitation. Transfection of wild-type HDAC2 in mutant cells reverted this epigenetic pattern by repressing the transforming genes in association with HDAC2 promoter occupancy. These results suggest a role for HDAC2 mutations in human tumorigenesis through the derepression of key genes from multiple cellular transformation pathways.
Insights
Inactivating mutations in histone deacetylase-2 (HDAC2) promote cancer by upregulating tumor-promoting genes. Restoring wild-type HDAC2 represses these genes, suggesting HDAC2
Area of Science:
- Epigenetics
- Cancer Biology
- Molecular Oncology
Background:
- Histone modification patterns are disrupted in human cancers.
- The role of histone-modifying enzymes in cancer generation is poorly understood.
- Histone deacetylase-2 (HDAC2) is implicated in epigenetic gene repression.
Purpose of the Study:
- To investigate the expression signature associated with HDAC2-truncating mutations in cancer cells.
- To determine the mechanistic role of HDAC2 mutations in tumorigenesis.
- To explore the potential of HDAC2 as a therapeutic target.
Main Methods:
- Unsupervised clustering analysis of microsatellite-unstable colorectal cancer cell lines.
- Gene expression microarray analysis to compare HDAC2 mutant and wild-type cells.
- Chromatin immunoprecipitation (ChIP) to assess HDAC2 recruitment and histone acetylation.
- Transfection experiments to restore wild-type HDAC2 function.
Main Results:
- HDAC2 mutant cells exhibit a distinct expression signature compared to wild-type cells.
- Upregulation of tumor-promoting genes (tyrosine kinases, cell cycle mediators, angiogenic factors) in HDAC2 mutant cells.
- Loss of HDAC2 recruitment and increased histone H4 hyperacetylation at the promoters of these genes.
- Restoration of wild-type HDAC2 reversed the epigenetic pattern and repressed oncogenic genes.
Conclusions:
- HDAC2 mutations contribute to human tumorigenesis by derepressing key genes involved in cellular transformation.
- HDAC2 plays a critical role in maintaining epigenetic silencing of tumor-promoting genes.
- Targeting HDAC2 may offer a therapeutic strategy for cancers with HDAC2-inactivating mutations.
Related Concept Videos
mTOR Signaling and Cancer Progression
The mTOR pathway or the...
mTOR Signaling and Cancer Progression
The mTOR pathway or the...
Abnormal Proliferation
Induced Pluripotent Stem Cells
Somatic cells are...
Adaptive Mechanisms in Cancer Cells
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...
Adaptive Mechanisms in Cancer Cells
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...
